Mymetics is focused on two pathways to develop prophylactic vaccines:
- The ability to build a first line of defence against viruses entering the blood stream by focusing on the mucosal layer.
- The development of a new vaccine delivery platform that does not use live attenuated or killed pathogens, while increasing the immunogenicity and stability of the vaccine.
Using these two pathways, our pipeline comprises 5 vaccine candidates at various stages of clinical development.
Our vaccine candidates for HIV/AIDS, malaria and the intra-nasal influenza are based upon the influenza virosomes, thereby using the influenza virosome as the carrier. While the RSV, Herpes Simplex and CMV vaccine candidates are based on their own natural virus and used directly as the vaccine.
RSV
Highly contagious virus and with a high prevalence in developed countries, causing respiratory tract infections in patients of all ages. There is currently no approved RSV vaccine available.
HIV / AIDS
With over 34 million victims, it is the fourth cause of mortality worldwide. Mymetics’ HIV vaccine is the first with a demonstrated ability to prevent viral transmission in primates.
Malaria
Malaria is an entirely preventable and treatable mosquito-borne illness, but still caused 627,000 deaths in 2012… we are developing a transmission blocking malaria vaccine
Intra-nasal Influenza
Influenza, commonly referred as flu, is a contagious respiratory illness caused by influenza viruses. It rapidly spreads around the world in seasonal epidemics and imposes a considerable economic burden in the form of hospital and other health care costs and lost productivity. In annual influenza epidemics, 5-15% of the population is affected with upper respiratory tract infections.
Herpes Simplex
HSV-1 is common (infecting 40-60% of people) and predominantly induces lip, mouth and facial blisters, or the genitalia. HSV-2 is more usually sexually transmitted and affects the genitalia in about 20% of the population...